FAMDF - Futura Medical plc
Other OTC - Other OTC Delayed price. Currency in USD
At close: 02:49PM EDT
Stock chart is not supported by your current browser
| Previous close | 0.6100 |
| Open | 0.8600 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.6100 - 0.6100 |
| 52-week range | 0.0100 - 1.0000 |
| Volume | |
| Avg. volume | 3,124 |
| Market cap | 178.473M |
| Beta (5Y monthly) | 1.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Highly positive FM71 Phase 3 study results with all primary and secondary endpoints achieved, MED3000 remains on track to submit for FDA marketing authorization
GUILDFORD, England, August 31, 2022--Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, today announces positive results from the confirmatory Phase 3 clinical study, "FM71" for MED3000, an investigational therapy for the treatment of erectile dysfunction ("ED").
